Proteomic studies on apoB-containing lipoprotein in cardiovascular research: A comprehensive review

Mass Spectrom Rev

9 Novembre Nov 2021 18 days ago
  • Gianazza E, Zoanni B, Mallia A, Brioschi M, Colombo GI, Banfi C

The complexity of cardiovascular diseases (CVDs), which remains the leading cause of death worldwide, makes the current clinical pathway for cardiovascular risk assessment unsatisfactory, as there remains a substantial unexplained residual risk. Simultaneous assessment of a large number of plasma proteins may be a promising tool to further refine risk assessment, and lipoprotein-associated proteins have the potential to fill this gap. Technical advances now allow for high-throughput proteomic analysis in a reproducible and cost-effective manner. Proteomics has great potential to identify and quantify hundreds of candidate marker proteins in a sample and allows the translation from isolated lipoproteins to whole plasma, thus providing an individual multiplexed proteomic fingerprint. This narrative review describes the pathophysiological roles of atherogenic apoB-containing lipoproteins and the recent advances in their mass spectrometry-based proteomic characterization and quantitation for better refinement of CVD risk assessment.

Reference

Proteomic studies on apoB-containing lipoprotein in cardiovascular research: A comprehensive review. Gianazza E, Zoanni B, Mallia A, Brioschi M, Colombo GI, Banfi C. Mass Spectrom Rev. 2021 Nov 8. doi: 10.1002/mas.21747

Go to PubMed